Peer to Peer Mentoring: Facilitating Individuals With Early Inflammatory Arthritis to Manage Their Arthritis: Peer Mentoring Program

Chronic Disease Clinical Trial

Official title:

Peer to Peer Mentoring: Facilitating Individuals With Early Inflammatory Arthritis to Manage Their Arthritis: Peer Mentoring Program

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01054131
• Other study ID #: 420-2009
• Status: Completed
• Phase: N/A
• First received: January 21, 2010
• Last updated: December 23, 2011
• Start date: January 2010
• Est. completion date: December 2011

Study information

• Verified date: December 2011
• Source: Sunnybrook Health Sciences Centre
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Ethics Review Committee
• Study type: Interventional

Clinical Trial Summary

Inflammatory arthritis (IA) is a major cause of long-term disability. Peer support may be a solution to the common problem of delayed treatment. Early peer support may result in improved use of therapy, higher self-efficacy, reduced anxiety, and improved coping in the first two years post-diagnosis. The whole intervention study comprises of two parts: The first part involves the development and testing of a peer mentor training initiative, which is called "Peer to Peer Mentoring: Facilitating Individuals with Early Inflammatory Arthritis to Manage their Arthritis - Peer Mentor Training". The second part, which is the focus of this study, involves the delivery of a one-on-one peer support intervention from a trained peer mentor to an individual newly diagnosed with EIA. The feasibility and acceptability of the program will be determined, as well as the health outcomes following the participation of the program.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: December 2011
• Est. primary completion date: September 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Have EIA disease duration within 6-52 weeks

2. At least 3 swollen joints, assessed by the treating rheumatologist, OR positive compression test for the metacarpophalangeal joints OR positive compression test for the metatarsophalangeal joints OR at least 30 minutes of morning stiffness

3. Prescription of a DMARD/biologic by the treating rheumatologist

4. Ability to speak and understand English without the aid of a secondary support person; AND

5. Capability to provide informed consent.

Exclusion Criteria:

1. IA disease duration less than 6 weeks or greater than 1 year

2. Previous or ongoing DMARD or biologic treatment

3. Inability to speak or read grade 6 English; AND

4. Inability to provide informed consent

Study Design

Intervention Model: Single Group Assignment, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Arthritis
• Chronic Disease
• Early Inflammatory Arthritis

Intervention

Behavioral:
• peer support
A quasi-experimental, before and after study design will obtain data for planning and implementing a larger-scale study. Exposures and outcomes will be measured at baseline, 3 months (immediate post 12-week program) and 6 months (3 months post-program). Ten individuals with EIA will be recruited by brief screening interviews to ensure they meet inclusion criteria. Each pair of peer mentor and EIA participant will meet at SHSC for an initial contact. EIA participants will receive informational, emotional and appraisal support from trained peer mentors by telephone or neutral private location at a time convenient for both parties, at least once a week for 12 weeks.

Locations

Country	Name	City	State
Canada	Sunnybrook Health Sciences Centre	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Sunnybrook Health Sciences Centre	Canadian Arthritis Network

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	DMARD adherence		0, 3, 6 months	No
Secondary	coping efficacy		0, 3 6 months	No
Secondary	self-management		0, 3, 6 months	No
Secondary	anxiety		0, 3, 6 months	No
Secondary	self efficacy		0, 3, 6 months	No
Secondary	social support		0, 3, 6 months	No